Pain Catastrophizing as a Cause for Systemic Inflammation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how negative thoughts affect the immune system in women with chronic pain.
A sub-study asks subjects to store a blood sample for future research by the PI aimed at identifying genetic markers in women with chronic pain.
| Condition | Intervention |
|---|---|
|
Chronic Musculoskeletal Pain |
Behavioral: Pain Catastrophizing Induction |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Pain Catastrophizing as a Cause for Systemic Inflammation |
- Pro-inflammatory and anti-inflammatory cytokine responses [ Time Frame: Study visit day only; measured at baseline, 1.5 hours, 2.5 hours, 3.5 hours, 4.5 hours ] [ Designated as safety issue: No ]
- Baseline measurement for mood, function, pain intensity, anxiety, and sleep quality [ Time Frame: Measured at baseline on study visit day. Pain intensity is tracked across the study day (baseline, 15 minutes, 1.5 hours, 2.5 hours, 3.5 hours, 4.5 hours). ] [ Designated as safety issue: No ]
- Changes in mood, function, and pain intensity across time [ Time Frame: These outcomes refer to the longitudinal portion of the study. In addition to measuring these outcomes on the study day as described above, we will be measuring these outcomes at 6-month intervals for up to 10 years. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Whole Blood, saliva
| Estimated Enrollment: | 60 |
| Study Start Date: | January 2009 |
| Estimated Study Completion Date: | June 2020 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Pain Catastrophizing Induction Group
Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest. Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress. Subsequent blood draws occur per protocol time points:
|
Behavioral: Pain Catastrophizing Induction
Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
|
|
Control Group
Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest. Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them. Blood draws and saliva samples gathered per protocol time points:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The study population will be 60 women between the age of 18 and 45 having chronic musculoskeletal pain
Inclusion Criteria:
- Women between the ages 18-45
- Non-smokers
- Diagnosed with musculoskeletal chronic pain
- Normal menstrual cycle
Exclusion Criteria:
- Psychosis or suicidality
- Current Major Depression
- Former intravenous drug user
- Needle/blood/injection phobia
- Limited venous access
- Sex-steroid dysregulation
- Self-Reported Pregnancy
- Fibromyalgia or inflammatory disease, e.g. lupus
- Active corticosteroid regimen
- Taking beta blockers
- Taking oral contraception or hormone therapy
Contacts and Locations| Contact: Beth Darnall, Ph.D | 503 494 4351 | darnallb@ohsu.edu |
| United States, Oregon | |
| Oregon Health and Science Universtiy | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Beth Darnall, Ph.D 503-494-4351 darnallb@ohsu.edu | |
| Contact: Kathy Parker, MSN 503-494-5224 parkerk@ohsu.edu | |
| Principal Investigator: Beth Darnall, Ph.D | |
| Principal Investigator: | Beth Darnall, Ph.D | Oregon Health and Science University |
More Information
No publications provided
| Responsible Party: | Beth Darnall, Ph.D., Oregon Health and Science University |
| ClinicalTrials.gov Identifier: | NCT00823147 History of Changes |
| Other Study ID Numbers: | 4920, 5 K12 HD04348807 |
| Study First Received: | January 13, 2009 |
| Last Updated: | September 11, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Oregon Health and Science University:
|
Pain Systemic Inflammation Pain Catastrophizing |
Additional relevant MeSH terms:
|
Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013